September 17 - 19, 2007 | The Fairmont, Washington , DC
doc title
Why You Should Attend
Why You Should Attend
Government and Industry Experts Share Experience on Issues that Matter Most:
HATCH-WAXMAN REFORM UPDATE: Q&A with US Congressman Henry A. Waxman in a pivotal year for new legislation
LOWER PRICED DRUGS ACT: Update and Q&A with US Senator Debbie Stabenow on removing hurdles that slow affordable generics from coming to market
WHAT'S HAPPENING ON CAPITOL HILL? Ramifications on the present and future of brand-generic settlements, authorized generics, follow-on biologics and more
THE FTC WEIGHS IN: Current antitrust actions involving the generics industry
EXECUTIVE ROUNDTABLE: Remaining competitive in a continuously changing market
A VIEW FROM WALL STREET: Review of 2007 and forecast for manufacturers and investors surrounding mergers, acquisitions, the global landscape and more